Research Analysts Issue Forecasts for CGTX FY2026 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – B. Riley issued their FY2026 earnings per share estimates for shares of Cognition Therapeutics in a research note issued to investors on Thursday, February 6th. B. Riley analyst M. Mamtani expects that the company will earn ($0.71) per share for the year. B. Riley has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. B. Riley also issued estimates for Cognition Therapeutics’ FY2027 earnings at ($0.68) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.54) EPS.

Other equities analysts have also recently issued reports about the stock. Chardan Capital restated a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a research report on Thursday, December 19th. HC Wainwright lifted their price objective on Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Thursday, December 19th. Finally, Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a research note on Monday, January 27th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Cognition Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $8.30.

Cognition Therapeutics Stock Down 1.9 %

Shares of CGTX stock opened at $0.64 on Friday. The stock has a 50 day simple moving average of $0.64 and a 200-day simple moving average of $0.64. Cognition Therapeutics has a 1-year low of $0.34 and a 1-year high of $2.95.

Hedge Funds Weigh In On Cognition Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new stake in Cognition Therapeutics in the 4th quarter valued at $26,000. Virtu Financial LLC purchased a new stake in shares of Cognition Therapeutics in the third quarter valued at about $27,000. Finally, Sigma Planning Corp increased its position in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after purchasing an additional 25,050 shares during the last quarter. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.